Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 66
Filtrar
1.
Rev. neurol. (Ed. impr.) ; 74(9): 303-311, May 1, 2022. ilus, tab, graf
Artigo em Espanhol | IBECS | ID: ibc-217697

RESUMO

La epilepsia con patrón catamenial se define como el aumento en la frecuencia de crisis epilépticas durante una etapa específica del ciclo menstrual respecto al basal. Se ha descrito que alrededor de un tercio de las mujeres con epilepsia presenta patrón catamenial. Los cambios en el patrón de crisis epilépticas se explicarían por la influencia de las fluctuaciones catameniales de las hormonas gonadales femeninas sobre la excitabilidad neuronal. La progesterona, a través de su metabolito alopregnanolona, desempeña un papel protector incrementando la transmisión gabérgica; sin embargo, su efecto en los receptores de progesterona cerebral puede incrementar la excitabilidad neuronal. Los efectos de los estrógenos son complejos y tienden a incrementar la excitabilidad neuronal, aunque dependen de su concentración y tiempo de exposición. Se han propuesto tres patrones catameniales de exacerbación de crisis epilépticas: el patrón perimenstrual, el patrón periovulatorio y el patrón lúteo. El abordaje diagnóstico se realiza mediante un proceso sistemático de cuatro pasos: a) historia clínica del patrón del ciclo menstrual y de las crisis epilépticas; b) métodos diagnósticos para caracterizar el ciclo menstrual y el patrón de las crisis epilépticas; c) comprobar los criterios diagnósticos, y d) categorizar el patrón catamenial. Las opciones de tratamiento estudiadas requieren mayor nivel de evidencia, y no existe ningún tratamiento específico aprobado por la Food and Drug Administration. Se recomienda la optimización del tratamiento anti crisis epilépticas convencional como primera opción terapéutica. Otras opciones terapéuticas, como tratamientos no hormonales y hormonales, podrían ser de utilidad en caso de que la primera opción terapéutica resulte ineficaz.(AU)


Catamenial pattern epilepsy is defined as an increase in the frequency of seizures during a specific stage of the menstrual cycle compared to baseline. It has been described that around a third of women with epilepsy have a catamenial pattern. The changes in the seizure pattern would be explained by the influence of catamenial fluctuations, of female gonadal hormones on neuronal excitability. Progesterone through its metabolite allopregnanolone plays a protective role by increasing GABAergic transmission; however, its effect on brain progesterone receptors can increase neuronal excitability. The effects of estrogens are complex, they tend to increase neuronal excitability, although their effects depend on their concentration and exposure time. Three catamenial patterns of seizure exacerbation have been proposed: the perimenstrual pattern, the periovulatory pattern, and the luteal pattern. The diagnostic approach is carried out through a systematic process of 4 steps: a) clinical history of the pattern of the menstrual cycle and epileptic seizures; b) diagnostic methods to characterize the menstrual cycle and the pattern of seizures; c) check diagnostic criteria; and d) categorize the catamenial pattern. The treatment options studied require a higher level of evidence, and there is no specific treatment. Optimization of conventional antiseizure treatment is recommended as the first therapeutic option. Other therapeutic options, such as non-hormonal and hormonal treatments, could be useful in case the first therapeutic option proves to be ineffective.(AU)


Assuntos
Humanos , Epilepsia , Ciclo Menstrual , Convulsões , Pregnanolona/farmacologia , Progesterona , Síndromes Epilépticas , Neurologia , Doenças do Sistema Nervoso
2.
Rev. iberoam. fertil. reprod. hum ; 39(2): 3-22, abril 2022. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-211152

RESUMO

Objetivo: Tanto el valor absoluto de progesterona (P) como el cociente progesterona/estradiol (P/E)son utilizados para el diagnóstico de la luteinización precoz (LP), sin llegar a un acuerdo en el umbraladecuado y con resultados muy dispares en cuanto a su capacidad predictiva. El cociente P/E ha creadoademás una gran confusión entre el concepto de LP y la baja respuesta ovárica a la hiperestimulación.La única alternativa viable es encontrar un parámetro que resulte independiente del grado de respuestaovárica y los valores de estradiol.Método:Se analizaron 434 ciclos consecutivos de FIV con estimulación mediante FSH y/o LH y fre-nado hipofisario con agonistas o antagonistas de GnRH sin ningún tipo de criterio de exclusión previopara determinar la relación matemática existente entre progesterona y estradiol en el momento previoa la ovulación.Resultados:La relación empírica entre progesterona y estradiol viene establecida por la fórmula E=4P2,de la que podemos deducir las fórmulas descriptivas de P=0,5E0,5, P/E=0,5E-0,5 y P2/E=0,25, siendoP2/E la única que corresponde a una constante sin dependencia del nivel de estradiol y, por tanto, el cri-terio ideal para el diagnóstico de LP. (AU)


Introduction: Both the absolute value of progesterone (P) and the progesterone/estradiol ratio (P/E) are used for the diag-nosis of early luteinization (EL), without reaching an agreement on the appropriate threshold and with very differentresults in terms of its predictive ability. The P/E ratio has also created a great deal of confusion between the concept of LPand low ovarian response to hyperstimulation. The objective of this study is to find a parameter that is independent of the degree of ovarian response and estradiol va-lues.Methods: We analyzed 434 consecutive IVF cycles with FSH and/or LH stimulation and pituitary down regulation withagonist or antagonists without any prior exclusion criteria to determine the mathematical relationship between progesteroneand estradiol at the time prior to ovulation.Results: The empirical relationship between progesterone and estradiol is established by the formula E=4P2, from whichwe can deduce the descriptive formulas of P=0,5E0,5, P/E=0,5E-0,5 an P2/E=0,25, being P2/E the only one that corres-ponds to a constant without dependence on the estradiol level and, therefore, the ideal criterion for the diagnosis of early. (AU)


Assuntos
Humanos , Progesterona , Estradiol , Luteinização , Diagnóstico
3.
Clín. investig. ginecol. obstet. (Ed. impr.) ; 49(2): 1-5, Abril - Junio, 2022. graf, tab
Artigo em Inglês | IBECS | ID: ibc-203194

RESUMO

The corpus luteum (CL) is a transitory endocrine structure found in female mammals which secretes progesterone (P4), rendering the endometrium secretory and thus facilitating embryo implantation in the uterus. CL insufficiency (CLI) is defined as a condition in which CL P4 cannot maintain the endometrium and gestation, causing infertility and pregnancy loss. The present study aimed to compare specific aspects related to CLI in humans and domestic animals to identify its main aetiological differences and those related to treatment of the condition in different species.


El cuerpo lúteo (CL) es una estructura endocrina transitoria que se encuentra en las hembras de mamíferos y que secreta progesterona (P4), volviendo al endometrio secretor y facilitando así la implantación del embrión en el útero. La insuficiencia de CL se define como una condición en la que CL P4 no es capaz de mantener el endometrio y la gestación, provocando infertilidad y pérdida del embarazo. El presente estudio tuvo como objetivo comparar aspectos específicos relacionados con la insuficiencia del CL en humanos y animales domésticos con el fin de identificar sus principales diferencias etiológicas y las relacionadas con el tratamiento de dicha condición en distintas especies.


Assuntos
Humanos , Animais , Feminino , Adulto , Ciências da Saúde , Infertilidade Feminina , Corpo Lúteo , Progesterona , Complicações na Gravidez , Fármacos para a Fertilidade Feminina , Obstetrícia
5.
Arch. med. deporte ; 38(201): 22-27, ene.-feb. 2021. tab, graf
Artigo em Inglês | IBECS | ID: ibc-201640

RESUMO

Serum ferritin has been proposed as a predictor of hepcidin concentrations in response to exercise. However, this fact has not been studied in physically-active women. Therefore, the main objective of this study was to analyse the hepcidin response at different ferritin status before and after running exercise in physically active females. Fifteen eumenorrheic women performed a 40-min running protocol at 75% of VO2peak speed in different menstrual cycle phases (early-follicular phase, mid-follicular phase and luteal phase). Blood samples were collected pre-exercise, 0h post-exercise and 3h post-exercise. For statistics, participants were divided into two groups according to their pre-exercise ferritin levels (< 20 and ≥ 20 μg/L). Through menstrual cycle, hepcidin was lower in both early follicular phase (p = 0.024; 64.81 ± 22.48 ng/ml) and mid-follicular phase (p = 0.007; 64.68 ± 23.91 ng/ml) for < 20 μg/L ferritin group, in comparison with ≥20 μg/L group (81.17 ± 27.89 and 79.54 ± 22.72 ng/ml, respectively). Hepcidin showed no differences between both ferritin groups in either pre-exercise, 0h post-exercise and 3h post-exercise. Additionally, no association between pre-exercise ferritin and hepcidin levels 3 h post-exercise (r = -0.091; p = 0.554) was found. Menstrual cycle phase appears to influence hepcidin levels depending on ferritin reserves. In particular, physically-active females with depleted ferritin reserves seems to present lower hepcidin levels during the early-follicular phase and mid-follicular phase. However, no association between ferritin and hepcidin levels was found in this study. Hence, ferritin levels alone may not be a good predictor of hepcidin response to exercise in this population. Multiple factors such as sexual hormones, training loads and menstrual bleeding must be taken into account


La ferritina sérica parece ser un predictor de la respuesta de la hepcidina al ejercicio. Sin embargo, este hecho no ha sido estudiado en mujeres físicamente activas. El objetivo fue analizar la respuesta de la hepcidina en diferentes estados de la ferritina antes y después del ejercicio. Quince mujeres eumenorreicas realizaron un protocolo de carrera de 40 minutos al 75% de la velocidad VO2pico en diferentes fases del ciclo menstrual (fase folicular temprana, fase folicular media y fase lútea). Se recogieron muestras de sangre antes del ejercicio y a las 0h y 3h después del ejercicio. Las participantes se dividieron en dos grupos según sus niveles de ferritina previos al ejercicio (< 20 y ≥ 20 μg/L). La hepcidina fue más baja tanto en la fase folicular temprana (p = 0,024; 64,81 ± 22,48 ng/ml) como en las fase folicular media (p = 0,007; 64,68 ± 23,91 ng/ml) para el grupo de ferritina < 20 μg/L en comparación con el grupo de ferritina ≥ 20 μg/L (81,17 ± 27,89 y 79,54 ± 22,72 ng/ml, respectivamen-te). La hepcidina no mostró diferencias entre ambos grupos de ferritina para ninguno de los momentos (antes del ejercicio ejercicio, 0h y 3h después del ejercicio). No se encontró ninguna asociación entre los niveles de ferritina previos al ejercicio y los niveles de hepcidina 3h posteriores al ejercicio (r = -0,091; p = 0,554). El ciclo menstrual parece influir en los niveles de hepcidina dependiendo de las reservas de ferritina. En particular, las mujeres físicamente activas con reservas de ferritina agotadas parecen presentar niveles de hepcidina más bajos durante la fase folicular temprana y la fase folicular media. Sin embargo, no se encontró ninguna asociación entre la ferritina y la hepcidina. Por lo tanto, los niveles de ferritina por sí solos pueden no ser un buen predictor de la respuesta de la hepcidina al ejercicio en esta población. Se deben tener en cuenta múltiples factores como las hormonas sexuales, las cargas de entrenamiento y el sangrado menstrual


Assuntos
Humanos , Feminino , Adulto , Treinamento de Força , Corrida/fisiologia , Ferritinas/sangue , Hepcidinas/sangue , Ciclo Menstrual/sangue , Consumo de Oxigênio/fisiologia , Índice de Massa Corporal , Valores de Referência , Fatores de Tempo , Estradiol/sangue , Progesterona/sangue
7.
Gac. sanit. (Barc., Ed. impr.) ; 35(supl. 2): S475-S478, 2021. tab
Artigo em Inglês | IBECS | ID: ibc-221080

RESUMO

Objective: This study aims to determine the relationship between estradiol hormone levels and duration of the usage on sexual dysfunction in Depo Medroxy Progesterone Acetate acceptors. Method: Family Planning (KB/Keluarga Berencana) Depo Medroxy Progesterone Acetate as many as 43 respondents who meet the sample criteria. The sampling technique used was accidental sampling. Data analysis was performed by using chi square. Results: The results showed that there was a significant relation between levels of the hormone estradiol and the incidence of sexual dysfunction (p = 0.000), as well as the length of time using Depo Medroxy Progesterone Acetate on sexual dysfunction (p = 0.000). Conclusion: The result of data analysis is that the duration of Depo Medroxy Progesterone Acetate injection usage significantly reduces the level of the hormone estradiol which can cause sexual dysfunction in Depo Medroxy Progesterone Acetate acceptors. (AU)


Assuntos
Humanos , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Progesterona , Estradiol , Disfunções Sexuais Fisiológicas , Acetatos , Acetato de Medroxiprogesterona , Medroxiprogesterona , Saúde Pública , Indonésia , Estudos Transversais , Inquéritos e Questionários
10.
Prog. obstet. ginecol. (Ed. impr.) ; 60(2): 130-132, mar.-abr. 2017.
Artigo em Espanhol | IBECS | ID: ibc-164052

RESUMO

Objetivo: presentar un caso de embarazo en una paciente con útero didelfo o bicorne bicollis tras ciclo de fecundación in vitro-microinyección intracitoplasmática de espermatozoides. Sujeto y método: paciente diagnosticada de útero didelfo mediante histerosalpingograma, histeroscopia y laparoscopia, a quien se realizó ciclo de fecundación in vitro-microinyección intracitoplasmática de espermatozoides por indicación masculina. Se recuperaron 9 ovocitos, 8 embriones, 5 embriones viables. TE: 1 embrión A en útero izquierdo y 1 embrión B en útero derecho. Resultados: Beta-HCG: 416 UI/l a los 14 días. Ecografía: gestación única evolutiva en útero izquierdo en semana 6. Cesárea en semana 38. Conclusiones: la fecundación in vitro en pacientes con útero didelfo se asocia a índices normales de gestación, pero a mayores tasas de aborto, parto prematuro y cesárea (AU)


Objective: Pregnancy after an in vitro fertilization treatment in a patient with uterus didelphis (bicornis bicollis). Subject and method: A patient with uterus didelphis diagnosed by hysterosalpingography, hysteroscopy and laparoscopy was underwent in vitro fertilization with intracytoplasmic sperm injection due to male infertility. 9 oocytes were recovered, 8 embryos, 5 of them viable. A double embryo transfer was performed: 1 grade A embryo was transferred to the left uterus and 1 B grade embryo to the right uterus. Results: After 14 days of embryo transfer a beta-hCG of 416 UI7L was obtained. Six weeks pregnancy ecography showed a single ongoing pregnancy in left uterus. Cesarean section was performed in 38th week of gestation. Conclusions: In vitro fertilization in patients with uterus didelphis is associated with normal pregnancy rates but higher abortion and premature delivery rates and cesarean section (AU)


Assuntos
Humanos , Feminino , Gravidez , Adulto , Útero/anormalidades , Fertilização In Vitro/métodos , Histeroscopia/métodos , Laparoscopia/métodos , Inseminação Artificial Homóloga , Injeções de Esperma Intracitoplásmicas/métodos , Transferência Embrionária/métodos , Progesterona/uso terapêutico , Ácido Fólico/uso terapêutico , Aspirina/uso terapêutico
12.
J. physiol. biochem ; 72(1): 33-44, mar. 2016. graf
Artigo em Inglês | IBECS | ID: ibc-168205

RESUMO

The role of aquaporin-4 (AQP4) and interleukin-6 (IL-6) in the development of brain edema post-traumatic brain injury (TBI) has been indicated. The present study was designed to investigate the effect(s) of administration of progesterone (P) and/or estrogen (E) on brain water content, AQP4 expression, and IL-6 levels post-TBI. The ovariectomized rats were divided into 11 groups: sham, one vehicle, two vehicles, E1, E2, P1, P2, E1 + P1, E1 + P2, E2 + P1, and E2 + P2. The brain AQP4 expression, IL-6 levels, and water content were evaluated 24 h after TBI induced by Marmarou’s method. The low (E1 and P1) and high (E2 and P2) doses of estrogen and progesterone were administered 30 min post-TBI. The results showed that brain water content and AQP4 expression decreased in the E1, E2, P1, and P2-treated groups. The administration of E1 decreased IL-6 levels. Addition of progesterone decreased the inhibitory effect of E1 and E2 on the accumulation of water in the brain. Administration of E1 + P1 and E1 + P2 decreased the inhibitory effect of E1 on the IL-6 levels and AQP4 protein expression. Our findings suggest that estrogen or progesterone by itself has more effective roles in decrease of brain edema than combination of both. Possible mechanism may be mediated by the alteration of AQP4 and IL-6 expression. However, further studies are required to verify the exact mechanism (AU)


No disponible


Assuntos
Humanos , Estrogênios/administração & dosagem , Lesões Encefálicas/metabolismo , Edema Encefálico/etiologia , Progesterona/administração & dosagem , Aquaporina 4/metabolismo , Interleucina-6/metabolismo , Lesões Encefálicas/complicações
13.
Clin. transl. oncol. (Print) ; 17(11): 895-902, nov. 2015. tab
Artigo em Inglês | IBECS | ID: ibc-143461

RESUMO

Purpose. In the literature, small number of study has addressed time of recurrence in breast cancer. We analyzed clinicopathological factors predicting early or late recurrence in breast cancer patients and also prognostic factors related with recurrence-free survival (RFS) in recurrent patients. Patients/methods. We evaluated retrospectively 1980 breast cancer patients. Relapsed was defined as early if it was occured first 5 year of follow-up (Group 1) and late if it was occured after 5 years (Group 2). The clinicopathological factors were compared in respect of time of recurrence. The prognostic factors were evaluated using univariate and multivariate analyses. Results. Recurrence wase detected in 141 patient during follow-up. Tumors recurred after 5 years more likely to have lower stage (p = 0.05), tumors without lymphovascular invasion (LVI) (p < 0.001) and perineural invasion (PNI) (p = 0.01), and also HER2 negative (p < 0.001). The median RFS time and 5 years RFS rates were 42.9 months and 31.9 %, respectively. LVI (p = 0.01), PNI (p = 0.03), HER2 (p = 0.003), progesterone receptor (PR) (p = 0.04), the presence of neoadjuvant chemotherapy (p = 0.003), adjuvant hormonotherapy (p = 0.05) were found to be related with RFS. Axillary lymph node metastasis (p = 0.05) and the presence of PNI (p = 0.009) were poor prognostic factors for early recurrent group. PR-positive tumors (p = 0.001) and luminal subtypes (p = 0.03) had instances of late recurrences significantly. Conclusions. Clinicopathological factors predicting the recurrence time in breast cancer were important to modify adjuvant therapy (AU)


No disponible


Assuntos
Feminino , Humanos , Pessoa de Meia-Idade , Neoplasias da Mama/complicações , Neoplasias da Mama/diagnóstico , Recidiva Local de Neoplasia/complicações , Recidiva Local de Neoplasia/diagnóstico , Progesterona/uso terapêutico , Terapia Neoadjuvante , Mastectomia/métodos , Seguimentos , Prognóstico , Estudos Retrospectivos , Análise Multivariada , Menopausa , Menopausa/fisiologia
14.
Neurología (Barc., Ed. impr.) ; 30(8): 510-507, oct. 2015. tab
Artigo em Espanhol | IBECS | ID: ibc-144221

RESUMO

Introducción: En el tratamiento de la epilepsia existen una serie de comorbilidades y grupos poblacionales (mujeres en edad fértil y ancianos) para los cuales podemos encontrar limitaciones en el manejo y precisar ajustes del tratamiento. Desarrollo: Búsqueda de artículos en Pubmed y recomendaciones de las Guías de práctica clínica en epilepsia y sociedades científicas más relevantes referentes la epilepsia en situaciones especiales (comorbilidades, mujeres en edad fértil, ancianos). Se clasifican las evidencias y recomendaciones según los criterios pronósticos del Oxford Center of Evidence-Based Medicine (2001) y de la European Federation of Neurological Societies (2004) para las actuaciones terapéuticas. Conclusiones: En las diversas comorbilidades, es necesaria una adecuada selección del tratamiento para mejorar la eficacia con el menor número de efectos secundarios. En la epilepsia catamenial es necesario un ajuste de la medicación antiepiléptica y/u hormonal, para poder controlar correctamente las crisis. La exposición a fármacos antiepilépticos durante la gestación aumenta el riesgo de malformaciones congénitas (MC) y puede afectar al crecimiento fetal y/o al desarrollo cognitivo. En el puerperio se aconseja la lactancia materna, vigilando los efectos adversos si se usan fármacos sedantes. Finalmente, los ancianos son una población muy susceptible de presentar epilepsia y que tiene unas características diferenciales con respecto a otros grupos de edad para el diagnóstico y el tratamiento. Estos pacientes pueden presentar con mayor frecuencia limitaciones terapéuticas por sus comorbilidades, pero suelen responder mejor al tratamiento y a dosis más bajas que en el resto de grupos de edad


Introduction: The characteristics of some population groups (patients with comorbidities, women of childbearing age, the elderly) may limit epilepsy management. Antiepileptic treatment in these patients may require adjustments. Development: We searched articles in Pubmed, clinical practice guidelines for epilepsy, and recommendations by the most relevant medical societies regarding epilepsy in special situations (patients with comorbidities, women of childbearing age, the elderly). Evidence and recommendations are classified according to the prognostic criteria of Oxford Centre of Evidence-Based Medicine (2001) and the European Federation of Neurological Societies (2004) for therapeutic interventions. Conclusions: Epilepsy treatment in special cases of comorbidities must be selected properly to improve efficacy with the fewest side effects. Adjusting antiepileptic medication and/or hormone therapy is necessary for proper seizure management in catamenial epilepsy. Exposure to antiepileptic drugs (AED) during pregnancy increases the risk of birth defects and may affect fetal growth and/or cognitive development. Postpartum breastfeeding is recommended, with monitoring for adverse effects if sedative AEDs are used. Finally, the elderly are prone to epilepsy, and diagnostic and treatment characteristics in this group differ from those of other age groups. Although therapeutic limitations may be more frequent in older patients due to comorbidities, they usually respond better to lower doses of AEDs than do other age groups


Assuntos
Adulto , Idoso de 80 Anos ou mais , Idoso , Feminino , Humanos , Masculino , Gravidez , Epilepsia/epidemiologia , Epilepsia/prevenção & controle , Prognóstico , Anticonvulsivantes/uso terapêutico , Complicações na Gravidez/tratamento farmacológico , Acetazolamida/uso terapêutico , Progesterona , Comorbidade , Sociedades Médicas/organização & administração , Sociedades Médicas/normas , Teratogênese , Período Pós-Parto , Período Pós-Parto/fisiologia , Aleitamento Materno/métodos
15.
Clin. transl. oncol. (Print) ; 16(10): 898-905, oct. 2014.
Artigo em Inglês | IBECS | ID: ibc-127609

RESUMO

PURPOSE: This study evaluated the effect of estrogen (E2), progesterone (P4), and the combination of them (E2 + P4) on survival rate, apoptosis, and the expressions of Bcl-2, hsa-let-7a and has-miR-34b in primary ovarian cancer cells to provide new clues for the clinical treatments of ovarian cancer. METHODS: The primary ovarian cancer cells from 60 cases of clinical ovarian cancer tissues were isolated and then cultured. The survival rate of ovarian cancer cells after the treatment of E2, P4 and E2 + P4 was analyzed by MTT assay. Cell apoptosis rate and cell cycle were measured by FACS analysis. Moreover, the relative abundance of Bcl-2 and microRNAs (let-7a, miR-34b) expressions were detected by quantitative real-time PCR (qRT-PCR) and Western blotting. RESULTS: Low concentrations of estrogen (10(-10), 10(-8), 10(-6 )mol/L) did not affect the proliferation of ovarian cancer cells. However, the high concentration of estrogen (10(-4 )mol/L) inhibited survival rate of ovarian cancer cells. Progesterone (10(-4 )mol/L) inhibited the proliferation of cancer cells. The combination of estrogen and progesterone significantly inhibited the survival rate of ovarian cancer cells with a time- and dose-dependent manner. High concentration of estrogen combined with progesterone (E2 + P4) induced apoptosis of ovarian cancer cells. E2 + P4 promoted the expression of let-7a and miR-34b and reduced the expression of Bcl-2 in ovarian cancer cells. When the expression of let-7a or/and miR-34b was inhibited using miRNA inhibitors, E2 + P4 treatment did not change the protein level of Bcl-2. CONCLUSION: E2 + P4 significantly inhibited the cell survival, promoted the cell apoptosis, induced the expression of let-7a and miR-34b, and reduced the expression of Bcl-2 in ovarian cancer cells (AU)


No disponible


Assuntos
Humanos , Feminino , Neoplasias Ovarianas/diagnóstico , Estrogênios , Progesterona , Western Blotting/instrumentação , Western Blotting/tendências , Western Blotting , Ovário , Ovário/patologia , Western Blotting/métodos , Western Blotting/normas
17.
J. physiol. biochem ; 70(2): 331-339, jun. 2014.
Artigo em Inglês | IBECS | ID: ibc-122955

RESUMO

Recent literature lacks studies on the effects of progesterone withdrawal on peripheral conversion of thyroxin (T4) into triiodothyronine (T3) by iodothyronine deiodinase 2 (D2) in different body tissues. The present study aimed to assess the possible relation of progesterone to T4, T3, and D2 in ovarectomized rats. Thirty female Wistar rats were included into a sham-operated control group and an ovarectomized group. Four months following the surgical procedures, measurements of estradiol, progesterone, free T4, free T3, and thyroid-stimulating hormone (TSH) were done. Also, estradiol/progesterone and T4/T3 ratios were calculated. Tissue homogenates from the kidney, liver, brain, thyroid, mandible, and femur were used to assess expression of D2 mRNA. The estradiol/progesterone ratio showed a significant increase in ovarectomized rats. T4 showed a significant increase in contrast to T3 which showed a highly significant decrease following ovariectomy. The T4/T3 ratio was significantly increased in ovarectomized rats. In addition, D2 expression was significantly attenuated in all tissue homogenates of the ovarectomized group. The present work showed a significant positive correlation between T4 and T3 in the sham-operated control rats, which was abolished in ovarectomized rats. A negative significant correlation between progesterone and T4 was revealed in ovarectomized rats. There was also a significant positive correlation between progesterone and D2 expression in the ovarectomized group. The results of the present study hypothesize that progesterone withdrawal may underlie the decrement in D2 expression, with consequent reduction in the peripheral conversion of T4 into T3 leading to a hypothyroid state


Assuntos
Animais , Ratos , Elementos Reguladores de Transcrição , Ovariectomia , Iodeto Peroxidase , Progesterona/farmacocinética , Estudos de Casos e Controles , Hipotireoidismo/fisiopatologia , Tiroxina , Tri-Iodotironina , Substâncias Protetoras/farmacocinética , Modelos Animais de Doenças
18.
Rev. esp. patol ; 46(4): 242-246, oct.-dic. 2013. ilus
Artigo em Espanhol | IBECS | ID: ibc-116181

RESUMO

El adenocarcinoma de glándulas anales es una entidad poco frecuente. Según la Organización Mundial de la Salud (OMS), la demostración de la continuidad entre las glándulas anales normales y las displásicas es el criterio más importante para el diagnóstico de dicha lesión, aunque hay pocos casos descritos en la literatura que cumplan este requisito. Describimos un caso de una mujer de 63 años con una masa anal indurada de 2 cm. El examen histológico reveló una neoformación de morfología ductal que afectaba predominantemente los estratos submucoso y muscular, en la que fue posible demostrar la continuidad entre glándulas anales normales y displásicas. Dicha lesión presentó intensa expresión de citoqueratina 7, mientras que CDX2 y citoqueratina 20 fueron negativos. El objetivo de este estudio es revisar la literatura para definir criterios útiles para el diagnóstico de esta inusual lesión (AU)


Anal gland carcinoma is a very rare entity. According to the World Health Organiza- tion (WHO), the most important criterion in its diagnosis is the continuity between normal and dysplastic anal glands. However, there are very few reported cases that fulfill this requirement. We report a case of a 63 year old woman with a 2 cm anal mass of hardened consistency. Histo- logically, a ductal neoplasm predominately in the submucosal and muscular layers was present in which it was possible to demonstrate the continuity between the normal and dysplastic anal glands. Immunohistochemistry revealed a strong positivity for cytokeratin 7 whilst CDX2 and cytokeratin 20 were negative. The aim of this study is to revise the literature in order to define useful diagnostic criteria for this unusual lesion (AU)


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Neoplasias do Ânus/diagnóstico , Neoplasias do Ânus/patologia , Carcinoma/patologia , Adenocarcinoma/patologia , Imuno-Histoquímica/métodos , Imuno-Histoquímica/normas , Imuno-Histoquímica , Canal Anal/patologia , Epitélio/patologia , Consentimento Livre e Esclarecido , Progesterona/análise , Progesterona , Neoplasias Ductais, Lobulares e Medulares/patologia
19.
Sanid. mil ; 69(3): 164-172, sept. 2013. graf
Artigo em Espanhol | IBECS | ID: ibc-116148

RESUMO

Introduction: Ischemic stroke leads adult’s mortality and long-term disability. Thus, new therapeutic approaches are needed. Estradiol (E2) and progesterone (P4) protect a variety of neuronal cells under stroke-like conditions in vitro; and the rodent brain against injury in vivo when administered prior to the ischemic insult, namely middle cerebral artery occlusion (MCAO). But, their therapeutic value after MCAO has been hardly studied. Less is known when coadministered under this paradigm. E2 and P4 also protect the neuronal cell death in vitro from ischemic-like injury, by reducing apoptotic cell death and enhancing cell survival signals. Here, we assessed the effect of combined E2 and P4 treatment in rats after permanent MCAO (pMCAO), which best mimics human ischemic stroke, analyzing the phosphatidylinositol 3-kinase (PI3-K)/Akt/glycogen synthase kinase 3 (GSK3)/ß-catenin signal pathway and the activation status of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in the infarct core (i.e., the ipsilateral frontoparietal cortex, ipsi-Ctx). Materials and Methods: Age-matched male Wistar rats (n=48) underwent pMCAO or sham operation and received either vehicle (ethanol 1% in saline) or combined E2 and P4 (0.04 mg/kg and 4 mg/kg, respectively) treatment at 6, 24, and 48 hrs after surgery. All animals were sacrificed 6 hrs after the last treatment dose and ipsi-Ctx homogenates were analyzed by immunoblotting. Results: pMCAO downregulated the PI3-K/Akt/GSK3/ß-catenin survival pathway and activated the proapoptotic protein SAPK/JNK in the ipsi-Ctx, effects which were reversed by E2 and P4 coadministration. Conclusions: Our data show that combined E2 and P4 treatment exerts a neuroprotective effect against brain injury when administered after the ischemic insult, which is mediated by modification of the activity of PI3-K/Akt/GSK3/ß-catenin signal pathway and that of SAPK/JNK. Hence, we provide experimental evidence that combined E2 and P4 comprise a potentially valuable therapeutic treatment for human ischemic stroke (AU)


Introducción: El ictus isquémico es una principal causa de muerte y discapacidad a largo plazo en adultos. Por tanto, es necesario desarrollar nuevas terapias. El estradiol (E2) y la progesterona (P4) protegen a distintas neuronas bajo condiciones que simulan el ictus isquémico in vitro; así como el cerebro de roedores cuando se administran antes del daño isquémico in vivo, en concreto antes de la oclusión de la arteria cerebral media (MCAO). Sin embargo, su valor terapéutico tras la MCAO ha sido poco estudiado. Menos se sabe aún acerca de su efecto cuando se coadministran en esta circunstancia. Además, el E2 y la P4 previenen la muerte neuronal por daño isquémico in vitro, disminuyendo la apoptosis y aumentando las señales de supervivencia. En este estudio, evaluamos en ratas el efecto del tratamiento combinado de E2 y P4 tras la MCAO permanente (pMCAO), ya que es el modelo que mejor simula el ictus isquémico humano, analizando la via de señalización fosfatidilinositol 3-kinasa (PI3-K)/Akt/glicógeno sintasa kinasa 3 (GSK3)/ß-catenina y la activación de la proteína kinasa activada por estrés/kinasa c-Jun N-terminal (SAPK/JNK) en el núcleo del infarto (es decir, el cortex ipsilateral frontoparietal, ipsi-Ctx). Materiales y Métodos: Ratas Wistar macho de edad similar (n=48) se sometieron a pMCAO u operación sham y recibieron vehículo (etanol 1% en salino) o tratamiento combinado de E2 y P4 (0.04 mg/kg y 4 mg/kg, respectivamente) a las 6, 24, y 48 h de la cirugía. Todos los animales se sacrificaron 6 h después de la última dosis y los lisados de ipsi-Ctx se analizaron por immunoblot. Resultados: La pMCAO disminuyó la actividad de la via de supervivencia PI3-K/Akt/GSK3/ß-catenina y activó la proteína proapoptótica SAPK/JNK en el ipsi-Ctx, efectos que fueron revertidos por la coadministración de E2 y P4. Conclusiones: Nuestros datos muestran que el tratamiento combinado de E2 y P4 ejerce un efecto neuroprotector en el cerebro cuando se administra tras el daño isquémico, que está mediado por la modificación de la actividad de la via PI3-K/Akt/GSK3/ß-catenina y de la de SAPK/JNK. Por tanto, ofrecemos la prueba experimental de que la combinación de E2 y P4 es una terapia potencialmente valiosa para el tratamiento del ictus isquémico en humanism (AU)


Assuntos
Humanos , Acidente Vascular Cerebral/tratamento farmacológico , Isquemia Encefálica/tratamento farmacológico , Estradiol/uso terapêutico , Progesterona/uso terapêutico , Combinação de Medicamentos , Fármacos Neuroprotetores/uso terapêutico , Córtex Cerebral
20.
Med. clín (Ed. impr.) ; 141(supl.1): 30-34, jul. 2013.
Artigo em Espanhol | IBECS | ID: ibc-140915

RESUMO

El objetivo principal del tratamiento en la mujer con mioma uterino es el control de los síntomas asociados como sangrado uterino anormal, dolor o presión. Aunque el coste y los posibles efectos adversos del uso a largo plazo del tratamiento médico pueden limitar su uso durante un tiempo prolongado, esta alternativa debe contemplarse antes de la indicación de un tratamiento quirúrgico. En la actualidad disponemos de una gran variedad de fármacos que, aunque no son un tratamiento específico para los miomas, pueden ser usados para el control del sangrado a corto-medio plazo, pero aún no hemos encontrado ninguna alternativa que permita eliminar la necesidad de tratamientos invasivos, por lo que es necesario continuar con la investigación en este campo. Dada la heterogeneidad de los miomas y la falta de tratamientos efectivos en el control de su crecimiento, la identificación de las señales que estimulan la iniciación y el crecimiento de este abre las puertas al desarrollo de nuevas terapias. Es posible que en el futuro se puedan diferenciar clases de miomas por técnicas moleculares y así aplicar el tratamiento específico, que controle su desarrollo y los síntomas asociados a él (AU)


The main objective of treatment in women with uterine fibroids is the control of associated symptoms such as abnormal uterine bleeding, pain and pressure. Although the cost and potential adverse effects of the long-term use of medical treatment may limit its use for a long time, this alternative should be considered before indicating surgical treatment. At present, we have a considerable variety of drugs that, although not specific treatments for fibroids, may be used for the short to medium-term management of bleeding; however, we have still not found an alternative that eliminates the need for invasive treatments. Further research in this field is therefore warranted. Given the heterogeneity of fibroids and the lack of effective treatments in controlling their growth, the identification of signals that stimulate the onset and growth of these fibroids opens doors to the development of new therapies. In the future we may be able to differentiate classes of fibroids by molecular techniques and thereby implement specific treatments that control their development and their associated symptoms (AU)


Assuntos
Feminino , Humanos , Estrogênios/uso terapêutico , Leiomioma/complicações , Leiomioma/cirurgia , Hemorragia Uterina/tratamento farmacológico , Hemorragia Uterina/etiologia , Neoplasias Uterinas/complicações , Neoplasias Uterinas/cirurgia , Progestinas/uso terapêutico , Terapia Combinada , Anticoncepcionais Femininos/uso terapêutico , Anticoncepcionais Orais Combinados/uso terapêutico , Anticoncepcionais Orais Hormonais/uso terapêutico , Moduladores de Receptor Estrogênico/uso terapêutico , Histerectomia , Levanogestrel/uso terapêutico , Norpregnenos/uso terapêutico , Progesterona/uso terapêutico , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...